Association of baloxavir marboxil prescription with subsequent medical resource utilization among school-aged children with influenza.
baloxavir marboxil
cap-dependent endonuclease inhibitor
comparative effectiveness research
influenza
medical resource use
neuraminidase inhibitor
pharmacoepidemiology
Journal
Pharmacoepidemiology and drug safety
ISSN: 1099-1557
Titre abrégé: Pharmacoepidemiol Drug Saf
Pays: England
ID NLM: 9208369
Informations de publication
Date de publication:
06 2021
06 2021
Historique:
revised:
15
02
2021
received:
04
08
2020
accepted:
16
02
2021
pubmed:
21
2
2021
medline:
25
11
2021
entrez:
20
2
2021
Statut:
ppublish
Résumé
Baloxavir marboxil is a novel antiviral agent for influenza, introduced into clinical practice in 2018. A concern remains about the variant virus with reduced susceptibility after baloxavir exposure and its clinical consequences such as healthcare-seeking behavior. Using a healthcare database in Japan, we compared the medical resource use following baloxavir and neuraminidase inhibitors (NAIs) treatment among children aged 7-15 years. The study period was from December 2018 to March 2019. The primary endpoint was the composite of hospitalization, laboratory and radiological tests, and antibiotic use over 1-9 days of antiviral treatment. As exploratory analyses, secondary outcomes being each single component of the primary composite were assessed and subgroup analyses comparing baloxavir with each NAI were done. Data from 115 867 prescriptions in 115 238 children were analyzed (median age: 10 years; severe influenza risk in 26%; baloxavir accounting for 43%). Overall, baloxavir use did not increase subsequent medical resource utilization in the composite endpoint (adjusted odds ratio [aOR]: 1.04; 95% confidence interval [CI]: 0.99-1.09; P = 0.14), as were likelihoods of other secondary outcomes. In the subgroup analysis, baloxavir use was associated with higher medical resource use than oseltamivir (aOR: 1.21; 95% CI: 1.13-1.31; P < 0.001) and lower resource use than zanamivir (aOR: 0.93; 95% CI 0.86-1.00; P = 0.040). Based on a single-year experience in Japan, prescribing baloxavir rather than NAIs did not increase medical resource utilization within 9 days of treatment, except in one exploratory comparison with oseltamivir.
Substances chimiques
Antiviral Agents
0
Dibenzothiepins
0
Morpholines
0
Pyridones
0
Triazines
0
baloxavir
4G86Y4JT3F
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
779-786Informations de copyright
© 2021 John Wiley & Sons Ltd.
Références
O'Hanlon R, Shaw ML. Baloxavir marboxil: the new influenza drug on the market. Curr Opin Virol. 2019;35:14-18.
Mushtaq A. Baloxavir: game-changer or much ado about nothing? Lancet Respir Med. 2018;6:903-904.
Mullard A. FDA approves first new flu drug in 20 years. Nat Rev Drug Discov. 2018 Nov;17:853.
Roche Group. Roche announces FDA approval of Xofluza (baloxavir marboxil) for people at high risk of developing influenza-related complications. https://www.roche.com/media/releases/med-cor-2019-10-18.htm. Accessed July 11, 2020.
Ministry of Health, Labour and Welfare in Japan. Monthly supply of antiviral drug against influenza (in Japanese). https://www.mhlw.go.jp/stf/seisakunitsuite/bunya/kenkou_iryou/kenkou/kekkaku-kansenshou01/jichitai.html. Accessed July 11, 2020.
Hayden FG, Sugaya N, Hirotsu N, et al. Baloxavir marboxil for uncomplicated influenza in adults and adolescents. N Engl J Med. 2018;379:913-923.
Uehara T, Hayden FG, Kawaguchi K, et al. Treatment-emergent influenza variant viruses with reduced Baloxavir susceptibility: impact on clinical and virologic outcomes in uncomplicated influenza. J Infect Dis. 2020;221:346-355.
Ison MG, Portsmouth S, Yoshida Y, et al. Early treatment with baloxavir marboxil in high-risk adolescent and adult outpatients with uncomplicated influenza (CAPSTONE-2): a randomised, placebo-controlled, phase 3 trial. Lancet Infect Dis. 2020;20:1204-1214.
National Institute of Infectious Disease in Japan. Detection of antiviral drug-resistant viruses in Japan during the 2018/2019 influenza season. https://www.niid.go.jp/niid/images/flu/resistance/20191128/dr18-19e20191126-1.pdf. Accessed July 11, 2020.
Gubareva LV, Baloxavir FAM. Treatment-emergent resistance: public health insights and next steps. J Infect Dis. 2020;221:337-339.
Omoto S, Speranzini V, Hashimoto T, et al. Characterization of influenza virus variants induced by treatment with the endonuclease inhibitor baloxavir marboxil. Sci Rep. 2018;8:9633.
Kasamo S, Takeuchi M, Ikuno M, et al. Real-world pharmacological treatment patterns of patients with young-onset Parkinson's disease in Japan. J Neurol. 2019;266:1944-1952.
Suchard MA, Schuemie MJ, Krumholz HM, et al. Comprehensive comparative effectiveness and safety of first-line antihypertensive drug classes: a systematic, multinational, large-scale analysis. Lancet. 2019;394:1816-1826.
National Institute of Infectious Disease in Japan. Infectious Agents Surveillance Report (in Japanese). https://nesid4g.mhlw.go.jp/Byogentai/Pdf/data2j.pdf. Accessed July 11, 2020.
Cromer D, van Hoek AJ, Jit M, Edmunds WJ, Fleming D, Miller E. The burden of influenza in England by age and clinical risk group: a statistical analysis to inform vaccine policy. J Infect. 2014;68:363-371.
Hardelid P, Verfuerden M, McMenamin J, Gilbert R. Risk factors for admission to hospital with laboratory-confirmed influenza in young children: birth cohort study. Eur Respir J. 2017;50:1700489.
Esposito S, Principi N. Oseltamivir for influenza infection in children: risks and benefits. Expert Rev Respir Med. 2016;10:79-87.
Huebner M, le Cessie S, Schmidt C. Vach W on behalf of the topic group “initial data analysis” of the STRATOS initiative (2018): a contemporary conceptual framework for initial data analysis. Observ Stud. 2018;4:171-192.
Huebner M, Vach W, le Cessie S, Schmidt CO, Lusa L. Topic group “initial data analysis” of the STRATOS initiative (STRengthening analytical thinking for observational studies, http://www.stratos-initiative.org). Hidden analyses: a review of reporting practice and recommendations for more transparent reporting of initial data analyses. BMC Med Res Methodol. 2020;13(20):61.
Bassetti M, Castaldo N, Carnelutti A. Neuraminidase inhibitors as a strategy for influenza treatment: pros, cons and future perspectives. Expert Opin Pharmacother. 2019;20:1711-1718.
Sun X, Ioannidis JP, Agoritsas T, Alba AC, Guyatt G. How to use a subgroup analysis: users' guide to the medical literature. JAMA. 2014;311:405-411.
Hirotsu N, Sakaguchi H, Sato C, et al. Baloxavir marboxil in Japanese pediatric patients with influenza: safety and clinical and virologic outcomes. Clin Infect Dis. 2020;71:971-981.
Kakuya F, Haga S, Okubo H, Fujiyasu H, Kinebuchi T. Effectiveness of baloxavir marboxil against influenza in children. Pediatr Int. 2019;61:616-618.
Sato M, Takashita E, Katayose M, Nemoto K, Sakai N, Hashimoto K, et al. Clinical and virological efficacy of Baloxavir Marboxil in children with influenza A. In: Options X for the Control of Influenza. August 28-Septenber 1, 2019, Singapore. Abstract 10510.
Saito R, Osada H, Chon I, Noshi T, Hara K, Sato I, et al. Clinical effectiveness of baloxavir marboxil compared to oseltamivir-appearance of mutated viruses at position 38 in PA protein for influenza A/H1N1pdm09 and A/H3N2. In: Options X for the Control of Influenza. August 28-September 1, 2019, Singapore. Abstract 11026.
Althouse AD. Adjust for multiple comparisons? It's not that simple. Ann Thorac Surg. 2016;101:1644-1645.
Rothman KJ. Six persistent research misconceptions. J Gen Intern Med. 2014;29:1060-1064.
Zhu VZ, Tuggle CT, Au AF. Promise and limitations of big data research in plastic surgery. Ann Plast Surg. 2016;76:453-458.
Hawkes N. Sixty seconds on … Baloxavir. BMJ. 2018;363:k4531.
Zaraket H, Saito R. Japanese surveillance systems and treatment for influenza. Curr Treat Options Infect Dis. 2016;8(4):311-328.
Urushihara H, Doi Y, Arai M, et al. Oseltamivir prescription and regulatory actions vis-à-vis abnormal behavior risk in Japan: drug utilization study using a nationwide pharmacy database. PLoS One. 2011;6:e28483.
Harrington R, Adimadhyam S, Lee TA, Schumock GT, Antoon JW. The relationship between Oseltamivir and suicide in pediatric patients. Ann Fam Med. 2018;16:145-148.
Cook JA, Collins GS. The rise of big clinical databases. Br J Surg. 2015;102:e93-e101.
Harbaugh CM, Cooper JN. Administrative databases. Semin Pediatr Surg. 2018;27:353-360.
Yamana H, Moriwaki M, Horiguchi H, Kodan M, Fushimi K, Yasunaga H. Validity of diagnoses, procedures, and laboratory data in Japanese administrative data. J Epidemiol. 2017;27:476-482.